PRESS RELEASE OBTAINED FROM BRIDGEBIO SITE – INVESTOR.BRIDGEBIO.COM – At the highest dose level evaluated to date (Cohort…
QED
April 25, 2022
The Perfect Date: National DNA Day
The perfect date: April 25th…because it’s not too hot, not too cold. All you need is a light…
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births.…
SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today…
March 27, 2020
QED COVID-19 Update
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope…
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy…
The Chandler Project (TCP) provides those affected with achondroplasia, and other forms of skeletal dysplasia (dwarfism), with the latest in pharmaceutical research and surgical advancements. Since 2019, TCP has hosted the only conference in North America that brings together individuals and their families, physicians, researchers, biotech industries and more together at the annual Achondroplasia Research Conference.